loader
Please Wait
Applying Filters...
menu
    • menu

    Annual Sales of Antihemophilic Factor Human reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Antihemophilic Factor Human

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 5Advate

    02 5Kogenate/Kovaltry/ Jivi

    03 2Recombinate

    04 6Refacto AF/Xyntha

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Advate

    Antihemophilic Factor (Recombinant)

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Advate

    Japan
    arrow
    Discovery on Target
    Not Confirmed

    Takeda

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Hematology

    Currency : USD

    2019 Revenue in Millions : 1,443

    2018 Revenue in Millions : 0

    Growth (%) : N/A

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Refacto AF/Xyntha

    Antihemophilic Factor (Recombinant)

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Refacto AF/Xyntha

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Pfizer Inc.

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Rare Disorders

    Currency : USD

    2019 Revenue in Millions : 426

    2018 Revenue in Millions : 514

    Growth (%) : -17

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Kogenate/Kovaltry/ Jivi

    Antihemophilic Factor (Recombinant)

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Kogenate/Kovaltry/ Jivi

    Germany
    arrow
    Discovery on Target
    Not Confirmed

    Bayer

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Rare Disorders

    Currency : USD

    2020 Revenue in Millions : 1,029

    2019 Revenue in Millions : 1,067

    Growth (%) : -4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Refacto AF/Xyntha

    Antihemophilic Factor (Recombinant)

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Refacto AF/Xyntha

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Pfizer Inc.

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Rare Disorders

    Currency : USD

    2020 Revenue in Millions : 370

    2019 Revenue in Millions : 426

    Growth (%) : -13

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Kogenate/Kovaltry/ Jivi

    Antihemophilic Factor (Recombinant)

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Kogenate/Kovaltry/ Jivi

    Germany
    arrow
    Discovery on Target
    Not Confirmed

    Bayer

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Rare Disorders

    Currency : USD

    2021 Revenue in Millions : 906

    2020 Revenue in Millions : 1,029

    Growth (%) : -3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Advate

    Antihemophilic Factor (Recombinant)

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Advate

    Japan
    arrow
    Discovery on Target
    Not Confirmed

    Takeda

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Hematology

    Currency : USD

    2020 Revenue in Millions : 1,253

    2019 Revenue in Millions : 1,473

    Growth (%) : -15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Refacto AF/Xyntha

    Antihemophilic Factor (Recombinant)

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Refacto AF/Xyntha

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Pfizer Inc.

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Rare Disorders

    Currency : USD

    2021 Revenue in Millions : 304

    2020 Revenue in Millions : 370

    Growth (%) : -18

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Advate

    Antihemophilic Factor (Recombinant)

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Advate

    Japan
    arrow
    Discovery on Target
    Not Confirmed

    Takeda

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Hematology

    Currency : USD

    2021 Revenue in Millions : 1,019

    2020 Revenue in Millions : 1,201

    Growth (%) : -9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Kogenate/Kovaltry/ Jivi

    Antihemophilic Factor (Recombinant)

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Kogenate/Kovaltry/ Jivi

    Germany
    arrow
    Discovery on Target
    Not Confirmed

    Bayer

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Hematology

    Currency : USD

    2022 Revenue in Millions : 889

    2021 Revenue in Millions : 906

    Growth (%) : -2

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Kogenate/Kovaltry/ Jivi

    Antihemophilic Factor (Recombinant)

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Kogenate/Kovaltry/ Jivi

    Germany
    arrow
    Discovery on Target
    Not Confirmed

    Bayer

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Rare Diseases

    Currency : USD

    2023 Revenue in Millions : 801

    2022 Revenue in Millions : 889

    Growth (%) : -13

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF